Navigation Links
Optimizing cell therapy against tumors is a balancing ACT

Adoptive cell transfer (ACT) therapy is used to treat patients with metastatic solid tumors. ACT involves the removal of some of the patient's cancer cells, and some of their immune T cells. When the cells are mixed together, specific parts of the cancer cells that stimulate the T cells to cause an immune attack can be identified. The T cells get expanded and re-infused into the patient to mount an immunological, anti-cancer response against the tumors. One of the challenges faced is selecting the appropriate T cells with proper antigen specificity.

In a new study appearing in the June 1 print issue of The Journal of Clinical Investigation, Nicholas Restifo and colleagues identified which cells are optimal for treating large, vascularized, established tumors. The authors use a mouse model that mimics the human clinical situation. They find that phenotypic and functional qualities of T cells are associated with the ability of ACT to cause regression of large, established melanomas. Seemingly paradoxical, naïve and early effector T cells are more effective for tumor treatment than more differentiated T cells.

In an accompanying commentary, Daniel Speiser and Pedro Romero write, "optimal therapeutic efficacy may depend on different T cell selection and preparation strategies" and these findings indicate that a pragmatic strategy for ACT is to keep the in vitro T cell expansion phase as short as possible to keep them naïve. These findings are important for development of improved adoptive immunotherapy approaches for treating tumors and established infectious diseases.

TITLE: Acquisition of full effector function in vitro paradoxically impairs the in vivo anti-tumor efficacy of adoptively transferred CD8+ T cells

TITLE: Towards improved immunocompetence of adoptively transferred CD8+ T cells


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors

Post Your Comments:
(Date:11/3/2009)...November 4, 2009) For more than 25 years, all att...trombus gigas ) have been unsuccessfuluntil now. F...echniques to produce beaded (nucleated) and non-be...n developed by scientists from Florida Atlantic Un...HBOI). With less than two years of research and ex...
(Date:11/3/2009)...ser labeling of fruit and vegetables is a new, pat...ide laser beam is used to label, or "etch" informa...common sticker-type labels. The technology has bee...tables and is being used in New Zealand, Australia...oved in Asia, South Africa, Central and South Amer...
(Date:11/3/2009)...UCLA Henry Samueli School of Engineering and Appli...constituted in the laboratory the enzyme responsib...ing drug lovastatin. , The research, publishe...lly lead to the development of other compounds wit...tin-synthesizing enzyme is one of the most interes...
Breaking Biology News(10 mins):Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2MicroRNAs help control HIV life cycle 9008 1MicroRNAs help control HIV life cycle 9008 2University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 1University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 2University of Maryland Company Trauma Solutions Named Finalist in 24250K Draper Fisher Jurvetson and Cisco Systems Global Business Plan Competition 50088 3Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 50085 1Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 50085 2Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 50085 3Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 50085 4Diagnostic Center of Medicine Selects Allscripts Electronic Health Record and Practice Management Solution 50085 5
...Ore. Can a patient-centered, care management prog...inary teams, supported by electronic tracking and ...s and hospitalizations among chronically ill older...involving more than 3,400 chronically ill seniors ...er David A. Dorr, M.D. appears to be "yes." , Th...
...erson who reminds you to floss might be your cardi...nown for some time that a protein associated with ...o are at risk for heart disease. But where,s the i...talian and U.K. scientists published online in Th...ne place. Indeed, proper dental hygiene should red...
...Dec. 15, 2008) -- In the aftermath of a heart atta...re heart failure. Authors of a new study believe t...ant role in a process that replaces dead heart mus...re hopeful that the findings will lead to the deve... "The body tries to fix the injury to the heart m...
Other Biology News:Proactive care saves lives of seniors, study finds 2Proactive care saves lives of seniors, study finds 3Reducing the damage of a heart attack 2
(Date:11/6/2009)...LLEY, Calif., Nov. 6 Calbiotech, I...ll Business Innovative Research (SBIR) Phase I con...al command. Under terms of the agreement, Calbiote...or the diagnosis of Dengue virus. ,, Dengue ...s a major threat to military forces deployed to tr...
(Date:11/5/2009)...TION -- Gone hybrid . . . , Fuel economy ratin... posted at the www.fueleconomy.gov web site, whi...ntains for the U.S. Department of Energy and the U...op 10 vehicles on the best fuel economy list are h...ity; 48 highway). "This list proves that hybrids h...
(Date:11/5/2009)..., Nov. 5 Imagenetix, Inc... William Spencer, President and CEO of Imagenetix,... annual LD MICRO Conference on Thursday, December ...eles. ,, About LD MICRO ,, LD MICRO is a by-...nding undervalued companies in the micro-cap space...
(Date:11/5/2009)... N.Y., Nov. 5 BioSpecifi...aceutical company developing first-in-class collag...l results for the third quarter ended September 30...eptember of this year, the FDA,s Arthritis Advisor...12-0, the approval of XIAFLEX(TM) for the treatmen...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
...S, N.J., Nov. 16 Genta,Incorporated (Nasdaq: GNT...nation letter from the NASDAQ Stock Market stating...isting from The NASDAQ Global,Market because the C...ntain,a minimum $10,000,000 value in stockholders,...3). The Company intends to provide a plan to,NASDA...
...t has led in the discovery of genes that confer ri... to explore their own genome W..., Nov. 16 deCODE genetics,(Nasdaq: DCGN ) today ...,service that enables individuals to get a detaile...tion to deCODEme(TM), you can learn what your DNA,...
.... 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp...es for Dr. Donald Segal and,John Docherty. Effecti...Officer and President formerly held by Dr. Segal w... Company,s Chief Executive Officer and Mr.,Dochert...es are being made as we strive to expand our corpo...
Other Biology Technology:Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market 2Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market 3deCODE Launches deCODEme(TM) 2deCODE Launches deCODEme(TM) 3deCODE Launches deCODEme(TM) 4Helix BioPharma Corp. announces management changes 2
DNP-X acid, SE -- [6-(2,4-Dinitrophenyl)aminohexanoic acid, succinimidyl ester] from AnaSpec
Mouse Anti-Laminin beta-2 Monoclonal Antibody, Unconjugated, Clone C4 from Santa Cruz Biotechnology, Inc.
Rabbit Anti-ZO-2 (H-110) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Goat Anti-TNFalpha-IP 2 (G-17) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: